| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
|
| ln Vitro |
In PC12 cells and primary cortical neurons, hypoxia/glucose deprivation (OGD) or NMDA-induced NGF differentiation is considerably attenuated by trimiprosate (200 μg/mL, 40 μg/mL, 8 μg/mL, and 1.6 μg/mL; 1 hour). Tramiprosate suppresses the translocation of nNOS from the cytoplasm to the membrane as well as the intensity of the interaction between nNOS and PSD95 [1].
|
|---|---|
| ln Vivo |
After MCAO, trimiprost (6.25–50 mg/kg; intraperitoneally; once) decreases infarct volume in a dose-dependent manner. Treatment with trimiprost (50 mg/kg) significantly improves neurological function [1].
|
| Animal Protocol |
Animal/Disease Models: Adult male SD (SD (Sprague-Dawley)) rats (200-250 g) undergoing middle cerebral artery occlusion (MCAO) [1]
Doses: 50 mg/kg, 25 mg/kg, 12.5 mg/kg, or 6.25 mg/kg administered Methods: intraperitoneal (ip) injection; Experimental Results: Infarct volume diminished in a dose-dependent manner after MCAO. |
| References |
[1]. Wu S et al. Tramiprosate protects neurons against ischemic stroke by disrupting the interaction between PSD95 and nNOS. Neuropharmacology. 2014 Aug;83:107-17.
[2]. Francine Gervais, et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47. [3]. R G Fariello, et al. Homotaurine (3 aminopropanesulfonic acid; 3APS) protects from the convulsant and cytotoxic effect of systemically administered kainic acid. Neurology. 1982 Mar;32(3):241-5. |
| Molecular Formula |
C3H9NO3S
|
|---|---|
| Molecular Weight |
139.17
|
| CAS # |
3687-18-1
|
| Related CAS # |
Tramiprosate-d6;1131576-06-1
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
NCCCS(=O)(O)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~20 mg/mL (~143.71 mM)
DMSO : ~1 mg/mL (~7.19 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 140 mg/mL (1005.96 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.1855 mL | 35.9273 mL | 71.8546 mL | |
| 5 mM | 1.4371 mL | 7.1855 mL | 14.3709 mL | |
| 10 mM | 0.7185 mL | 3.5927 mL | 7.1855 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
